Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection, healing, and repair. Key product lines include orthobiologics (joint health), ophthalmic viscoelastics, aesthetic dermatology, surgical anti-adhesion barriers, and veterinary products.
Strategic Development: In December 2009, Anika acquired Fidia Advanced Biopolymers S.r.l. ("FAB"), an Italian company, for approximately $33.9 million (cash and stock). This acquisition expanded Anika's portfolio to include advanced wound care, additional orthopedic regenerative medicine products, and ENT care, primarily commercialized in Europe.
Key Financial Metrics (Year Ended Dec 31, 2010)
| Metric | 2010 Value | 2009 Value |
|---|---|---|
| Total Revenue | $55.6 million | $40.1 million |
| Product Revenue | $52.7 million | $37.3 million |
| Net Income | $4.3 million | $3.7 million |
| Diluted EPS | $0.32 | $0.32 |
| Product Gross Margin | 55% | 63% |
| Operating Cash Flow | $7.9 million | $3.1 million |
| Cash & Equivalents | $28.2 million | $24.4 million |
| Working Capital | $37.0 million | $33.3 million |
| Long-Term Debt | $12.8 million | $14.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 38% to $55.6 million, driven primarily by the inclusion of FAB's results and an 18% organic growth in Anika's product revenue.
- Product Mix Shift: Orthobiologics revenue grew 34% to $30.7 million (58% of product revenue). Dermal revenue surged 142% to $3.6 million due to the addition of FAB's wound care products, though aesthetic dermatology revenue declined due to the bankruptcy of distributor Coapt Systems.
- Margin Compression: Product gross margin decreased from 63% to 55%. This was attributed to the inclusion of lower-margin FAB products, inventory write-downs ($480,000) related to the Coapt bankruptcy and MONOVISC delays, and duplicate manufacturing costs during the transition from Woburn to the new Bedford facility.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 64% to $17.3 million, largely due to FAB integration costs and infrastructure development. R&D expenses decreased 16% to $6.9 million as major MONOVISC clinical trials concluded in 2009.
- Customer Concentration: Five customers accounted for 82% of product revenue in 2010. Bausch & Lomb (B&L) represented 21% of revenue, but this is expected to decline significantly in 2011 following the expiration of their primary supply agreement.
Guidance, Outlook, Risks, and Contingencies
- Outlook for 2011: Management expects ophthalmic revenue to decline significantly due to the transition of B&L manufacturing to a low-cost supplier. However, they anticipate margin improvement through the commercialization of their own product, AnikaVisc. Orthobiologics revenue is expected to increase domestically and internationally.
- MONOVISC Regulatory Status: The FDA has identified deficiencies in the Premarket Approval (PMA) application for MONOVISC. Anika has requested a review by the Orthopedic Advisory Panel, but no meeting date has been set. Approval remains uncertain.
- Manufacturing Transition: The company is transitioning manufacturing from Woburn to a new facility in Bedford, MA. Validation is ongoing through 2011. This transition incurs duplicate costs and is expected to add over $2.2 million in annual depreciation once fully operational.
- Legal Proceedings:
- Genzyme Litigation: Genzyme sued Anika alleging patent infringement regarding MONOVISC. Anika denies liability and considers the risk of loss remote.
- Artes Medical Bankruptcy: A trustee is seeking to recover $360,000 in payments made by the former distributor Artes Medical. Anika contests this, viewing the risk as remote.
- Key Risks: Dependence on a small number of customers; failure to obtain FDA approval for MONOVISC and FAB products; integration challenges with FAB; and currency exchange fluctuations (approx. 20% of business in Euros).
Investor Verification Checklist
- MONOVISC Approval Timeline: Verify the status of the FDA Advisory Panel meeting and the likelihood of PMA approval, as this is critical for U.S. orthobiologics growth.
- Bausch & Lomb Revenue Impact: Confirm the magnitude of revenue decline from B&L in 2011 and the initial sales performance of the new AnikaVisc product.
- Bedford Facility Validation: Monitor the completion of FDA validation for the Bedford manufacturing facility to ensure no disruption in supply or further cost overruns.
- FAB Integration: Assess the progress of transferring FAB manufacturing to the U.S. and the realization of projected synergies and margin improvements.
- Debt Covenants: Review compliance with the Bank of America credit agreement covenants, particularly the quick ratio and fixed charge coverage ratio.